ABBV News 54.16 06/16/2014 04:21:33 Abbvie Inc. Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 54.16 $ABBV

AbbVie's NDA for investigational, all-oral, interferon-free regimen for treating hepatitis C virus accepted by the US FDA for priority review
M2 - 21 mins ago
Biopharmaceutical company AbbVie (NYSE:ABBV) disclosed on Friday that its New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for treating hepatitis C virus (HCV) infection has been accepted by the US Food and Drug Administration (FDA) for review.

Why Shorts Are Betting Against Enanta Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Sun Jun 15, 5:00PM CDT
Short interest is often a key metric that investors can use to gain some insight into how the Street feels about a particular stock. And when short interest picks up dramatically, it's generally a good idea to know why. Shares of little-known ...

Better Stock Today: Ford vs. AbbVie
Frank Thomas and David Williamson, The Motley Fool - Motley Fool - Sun Jun 15, 11:00AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Ford  takes on  AbbVie  for this first...

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire - Fri Jun 13, 2:34PM CDT
AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.

Could This Buyout Go Down As One of the Worst Deals Ever?
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 2:15PM CDT
You certainly don't have to look far these days to see that merger and acquisition activity is picking up across a number of sectors. Investors and Wall Street analysts love to see M&A activity because it signals two things. First, it points to...

How the U.S. Government Makes Money on Cannabis
at The Street - Fri Jun 13, 10:30AM CDT
The U.S. government holds a patent on cannabinoids and has collected money for licensing the patent. It could eventually collect thousands of dollars in royalties.

Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma
PR Newswire - Fri Jun 13, 6:10AM CDT
The trading session on Thursday, June 12, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the day 0.71% lower at 1,930.11. The losses were broad based as eight out of the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day 0.56% lower at 688.58, while the index has gained 1.97% in the previous one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Bristol-Myers Squibb Co. (NYSE: BMY) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on ABBV, ACRX, BMY and GWPH can be downloaded upon signing up at:

Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson...

Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free.

Bristol-Myers' RA Drug Orencia Encouraging - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 5:10PM CDT
Bristol-Myers' Orencia performed well in a phase IIIb study as a combination therapy.

Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs  in 2013. Big drug companies, such as AbbVie,  Johnson & Johnson  , and Amgen  , offer...

AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland
PR Newswire Europe - Wed Jun 11, 5:48AM CDT
-- EUR85 million investment creates greater manufacturing capacity to deliver new medicines for patients

AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases
PR Newswire - Wed Jun 11, 1:00AM CDT
AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.

AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire Europe - Tue Jun 10, 11:46PM CDT
-- New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas

Will Merck's Bold Hepatitis C Play Pay Off?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
There is a significant (and sometimes larger than expected) gap between "looks like it can compete" and actually competing with a rival that has both strong data and a big head start, but Merck continues to show that it is serious...

Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 12:10PM CDT
Merck's (MRK) decision to acquire Idenix (IDIX) for $24.50 per share in cash will boost its hepatitis C virus (HCV) pipeline.

Up 58%: Should You Buy Achillion Pharmaceuticals Today?
Michael Douglass and Matt Trogdon, The Motley Fool - Motley Fool - Tue Jun 10, 10:09AM CDT
Investors in  Achillion Pharmaceuticals  got a double-whammy of good news over the last two days, with  Merck 's purchase of fellow hepatitis c biotech  Idenix  pumping shares up over 40%. And Achillion is up over 50% today on further good news --...

AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference
PR Newswire - Tue Jun 10, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time.

Here's Why Merck Paid Triple the Price for Idenix
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 09, 6:15PM CDT
U.S. stocks put in another record high on Monday -- the ninth in 11 trading sessions -- as the benchmark S&P 500 and the narrower Dow Jones Industrial Average both rose 0.1%. The technology-heavy Nasdaq Composite Index gained 0.4%. ...

Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014
M2 - Mon Jun 09, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx5qq/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - UCB S.A. - Sandoz Inc. - Swedish Orphan Biovitrum AB - Biosidus S.A. - Genor BioPharma Co., Ltd. - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/zrx5qq/idiopathic
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 112

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 109

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 11

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 113

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Launch of RM11, a Game-Changer for Creators

Updated Category News Views 451

Introducing RM11: A New Era for Creators RM11 is an innovative digital platform crafted specifically for creators, prioritizing their needs and ensuring they keep more of their hard-earned money. With a comprehensive payout model allowing creators to retain 90% of earnings, RM11 focuses on fostering a vibrant ecosystem where creators thrive without excessive fees or...

Continue Reading
Tyfast Energy Secures Grant to Enhance Lithium-Ion Battery Tech

Updated Category News Views 174

Tyfast Energy Secures Funding for Advanced Battery Development Tyfast Energy, an innovative battery materials company, has achieved a significant milestone by securing a $100,000 grant aimed at enhancing its development of lithium-ion batteries. This funding, provided by the National Science Foundation's Energy Storage Engine, is expected to expedite the advancement of...

Continue Reading
DMG Blockchain Solutions Sets Stage for AI Growth with MOU

Updated Category News Views 285

DMG Blockchain Solutions Expands into Generative AI DMG Blockchain Solutions Inc. has recently made headlines with its agreement to acquire a 10-megawatt prefabricated data center. This significant advancement positions DMG as a key player in the growing field of Generative Artificial Intelligence (Gen AI). The memorandum of understanding (MOU) signifies a strategic step...

Continue Reading
EPAM Systems Achieves Steady Growth in 2024 Financial Results

Updated Category News Views 205

Financial Overview of EPAM Systems for 2024 EPAM Systems, Inc. (NYSE: EPAM), a premier digital transformation and product engineering company, has reported commendable financial results for the fourth quarter and full year of 2024. The company displayed resilience in its growth amid a changing economic landscape, showcasing a 7.9% increase in revenues year-over-year in...

Continue Reading
Carvana Stock Surges After Bullish Power Inflow Indicator

Updated Category News Views 242

Carvana Stock Gains After Bullish Indicator Carvana Co (NYSE: CVNA) experienced an exciting uptick in its stock price following a noteworthy signal known as the Power Inflow. This indicator, closely monitored by traders focused on order flow analytics, reflects significant shifts in buying momentum, particularly from both institutional and retail investors. The Power...

Continue Reading